Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.40
    +1.50 (+1.83%)
     

  • GOLD FUTURES

    2,335.70
    -10.70 (-0.46%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,344.63
    -79.98 (-0.15%)
     

  • CMC Crypto 200

    1,426.91
    +12.15 (+0.86%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

BUZZ-Galapagos at 6-mnth low on drug trial update

Reuters - UK Focus

** Shares in Galapagos (Other OTC: GLPGF - news) slip as much as 6.7 percent to a near six-month low following update on drug candidates.

** Galapagos says that drug candidate GLPG0974 did not show an improvement in symptoms of ulcerative colitis in a four-week study.

** Drug candidate GPLG0634 to treat rheumatoid arthritis has also taken longer than expected to secure national regulator approval to proceed with Phase 2 studies, results of which are due next year.

** KBC Securities said the delay for the latter might be small, but could deter investors and could add to uncertainty over whether partner AbbVie (Berlin: 4AB.BE - news) would take up the drug

ADVERTISEMENT

** For the former drug, the lack of clinical improvement meant Galapagos did not have a second mid-stage asset in its pipeline.

(Reuters messaging rm://philip.blenkinsop.thomsonreuters.com@reuters.net)